Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNiflumic acid
说明： Cyclooxygenase-2 (COX-2) inhibitor; GPR35 agonist
化学名： 2-[3-(Trifluoromethyl)anilino]nicotinic acid
生物活性 for Niflumic acid
Niflumic acid is a nonsteroidal anti-inflammatory drug (NSAID); selectively inhibits COX-2. Also activates human TRPA1 inducibly expressed in HEK293 cells; displays agonist activity at GPR35.
技术数据 for Niflumic acid
| 分子量 | 282.22 |
| 公式 | C13H9F3N2O2 |
| 储存 | Store at RT |
| CAS Number | 4394-00-7 |
| PubChem ID | 4488 |
| InChI Key | JZFPYUNJRRFVQU-UHFFFAOYSA-N |
| Smiles | O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for Niflumic acid
参考文献 for Niflumic acid
参考文献是支持产品生物活性的出版物。
Ottolia and Toro (1994) Potentiation of large conductance KCa channels by niflumic, flufenamic and mefenamic acids. Biophys.J. 67 2272 PMID: 7535111
Famaey (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm.Res. 46 437 PMID: 9427063
Hu et al (2010) Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs. Pflugers Arch. 459 579 PMID: 19888597
Deng et al (2012) Multiple tyrosine metabolites are GPR35 agonists. Sci.Rep. 2 373 PMID: 22523636
按标靶查看相关产品
按产品操作查看相关产品
关键词: Niflumic acid, Niflumic acid supplier, cyclooxygenase, 2, cox-2, inhibitors, inhibits, Cyclooxygenase, GPR35, 4112, Tocris Bioscience
5 篇 Niflumic acid 的引用文献
引用文献是使用了 Tocris 产品的出版物。 Niflumic acid 的部分引用包括：
Rayner et al (2019) Mechanism and effects of pulsatile GABA secretion from cytosolic pools in the human beta cell. Nat Metab 1 1110-1126 PMID: 32432213
Ute et al (2022) Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers. Exp Dermatol 31 1477-1499 PMID: 35913427
Cao et al (2014) SLC17A9 protein functions as a lysosomal ATP transporter and regulates cell viability. J Neuroinflammation 289 23189 PMID: 24962569
Xi et al (2020) Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth. J Exp Med 217 PMID: 32097463
Amjad et al (2015) Conditional knockout of TMEM16A/anoctamin1 abolishes the calcium-activated chloride current in mouse vomeronasal sensory neurons. J Gen Physiol 145 285 PMID: 25779870
Niflumic acid 的评论
平均评分: 5 (Based on 1 Review.)
Have you used Niflumic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Niflumic acid increases non-selective cationic current in cardiomyocytes.
By
Chintan Koyani on 10/23/2018
分析类型： In Vitro
种属： Other
细胞系/组织： Cardiomyocytes
Non-selective cationic current was measured in guinea pig cardiomyocytes before and after superfusion with 100 µM niflumic acid for 10 min. Compared to time matched rundown, niflumic acid significantly increased inward as well as outward non-selective cationic current in cardiomyocytes.
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.